Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Abbott Laboratories (NY:ABT)

102.73 +0.37 (+0.36%)
Streaming Delayed Price Updated: 2:30 PM EDT, Sep 17, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Abbott Laboratories

< Previous 1 2 3 4 5 6 7 8 9
...
52 53 Next >
News headline image
JEPI and JEPQ Yield Way More Than SCHD, but SCHD Could Produce More Passive Income Over the Long Term. Here's Why. ↗
Long-term holders of the Schwab U.S. Dividend Equity ETF have seen their yield on cost gradually rise. 
Via The Motley Fool
Topics Bonds ETFs Regulatory Compliance
News headline image
Is AbbVie the Best Dividend King to Buy in September? ↗
It is certainly a good Dividend King to buy in September. 
Via The Motley Fool
Topics Intellectual Property
News headline image
SCHD's Stunning Reversal: Schwab's Flagship Dividend ETF Is Up 29% and Climbing ↗
Given what's going on in the world and in the market, perhaps it's natural that SCHD is surging. 
Via The Motley Fool
Topics Artificial Intelligence ETFs World Trade
Abbott Laboratories (NYSE:ABT) Clears All Quality Investing Hurdles ↗
Via Chartmill
Abbott Laboratories (NYSE:ABT): A Strong Candidate for Quality Investors ↗
Via Chartmill
News headline image
If a Stock Market Crash Is Coming, Investors Will Want to Own This Dividend King ↗
Worried about a pullback? This Dividend King pairs a 54-year streak with catalysts that could provide income even if the market crashes. 
Via The Motley Fool
News headline image
Moderna Just Doubled Overnight, and 2 More Healthcare Stocks Could Follow It ↗
Moderna, Pharvaris and AbbVie span short, mid and long-term healthcare setups, from melanoma data to a Phase 3 catalyst and 13 straight years of dividend hikes. 
Via MarketBeat
Topics Artificial Intelligence Bonds
News headline image
3 Dividend Stocks to Buy and Hold Forever (Including 1 Dividend King) ↗
Owning these dividend stocks could be a simple way to make money over the long term. 
Via The Motley Fool
Topics Intellectual Property
News headline image
If the AI Boom Slows Down, History Says This Is the Smartest Way to Protect Your Long-Term Portfolio ↗
The Schwab US Dividend Equity ETF is a safe all-weather investment. 
Via The Motley Fool
Topics Artificial Intelligence ETFs Economy
News headline image
Just Starting Out With $5,000? 3 Magnificent ETFs to Buy in 2026. ↗
These 3 ETFs would give you a strong long-term portfolio to build from. 
Via The Motley Fool
Topics ETFs
News headline image
Billionaire Ken Griffin Increased His Stake in This Dividend King by 547% in Q2. Wall Street Thinks It's Still a Buy. ↗
His AbbVie purchase was a big move into a high-yielding dividend stock. 
Via The Motley Fool
News headline image
Billionaire Ken Griffin Just Loaded Up on AbbVie and Abbott. Here's Whether Investors Should Follow His Lead. ↗
AbbVie and Abbott stand out as strong healthcare investments because they combine established businesses with long-term growth opportunities. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Better Dividend King to Buy Right Now: Abbott Labs or Johnson & Johnson? ↗
These two high-quality dividend payers have had very different fortunes recently. 
Via The Motley Fool
Topics Lawsuit
News headline image
Recent Report Shows That Rep. Rick Allen Sold Up to $50K Worth of Abbott Laboratories Stock ↗
An official report on August 18, 2026 reveals Representative Rick Allen's recent sale of Abbott Laboratories (NYSE:ABT) stock, valued between $15,001 and $50,000. The transaction took place on July 14,... 
Via Benzinga
News headline image
If You Invest $100 a Month in SCHD, Here's the Passive Income It Could Deliver in 20 Years ↗
This top dividend ETF is still a reliable long-term income investment. 
Via The Motley Fool
Topics ETFs Retirement Stocks
News headline image
Recent Report Shows That Rep. Richard Dean Dr McCormick Sold Up to $375K Worth of Abbott Laboratories Stock ↗
Records from August 14, 2026 indicate that Representative Richard Dean Dr McCormick of Georgia made a sale of Abbott Laboratories (NYSE:ABT), valued between $25,025 and $375,000, with the transaction... 
Via Benzinga
News headline image
The L.A. Lakers Delivered a 1-Year Return of 25%. These ETFs Have Done Even Better. ↗
Most people don't have $12.5 billion to buy the L.A. Lakers. But with stock ETFs, you could earn a higher return than the Lakers' owners. 
Via The Motley Fool
Topics Artificial Intelligence ETFs Economy
News headline image
Recession-Proofing Your Portfolio Before the Storm Hits ↗
Whether a recession is coming in 2026 or five years from now, the best investors are always figuring out how to prepare. 
Via The Motley Fool
Topics Economy
News headline image
The U.S. Labor Market Is Weakening. These 2 Dividend Stocks Look Built to Weather a Recession ↗
These stocks can help you withstand (almost) any storm. 
Via The Motley Fool
Topics Economy
News headline image
AbbVie Piles on $8 Billion in Debt for Its Apogee Deal -- Should Dividend Investors Worry? ↗
The pharmaceutical company hopes that another big-time acquisition will pay off. 
Via The Motley Fool
News headline image
AbbVie vs. Abbott Laboratories: Which Healthcare Stock Is a Better Buy in 2026? ↗
AbbVie generates stronger free cash flow and trades at a lower forward multiple, while Abbott offers diversification and a healthier balance sheet. 
Via The Motley Fool
News headline image
Solventum Nears Inflection Point As It Begins to Unlock Value ↗
Solventum shares gain on strong Q2 revenue, earnings, and cash flow, buybacks, and improved guidance, with analysts raising price targets amid a discounted valuation versus med/tech peers. 
Via MarketBeat
Topics Initial Public Offering
News headline image
This Stock Keeps Raising Its Dividend No Matter What the Market Does -- and Wall Street Thinks It's a Buy Right Now ↗
There is no end in sight for the drugmaker's dividend growth streak. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Abbott Laboratories vs. Eli Lilly: Which Healthcare Stock Is a Better Buy in 2026? ↗
Abbott trades at half Lilly's valuation multiple, but Lilly's 45% revenue surge and 32% net margin raise the stakes for growth-focused investors. 
Via The Motley Fool
News headline image
Abbott Laboratories vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026? ↗
Abbott trades at a cheaper valuation but carries higher litigation risk, while J&J boasts superior profitability despite a pending talc settlement. 
Via The Motley Fool
News headline image
3 Dividend Stocks to Buy for a Lifetime of Passive Income ↗
These companies' recent headwinds shouldn't lead to decreased payouts. 
Via The Motley Fool
Topics Intellectual Property
News headline image
AbbVie Has Raised Its Dividend for 53 Straight Years and Still Looks Attractively Valued. Is This Dividend King the Smartest Buy in Healthcare Right Now? ↗
AbbVie still looks like a compelling buy at its all-time high. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Why Wall Street Can't Get Enough of This Dividend King ↗
AbbVie has an attractive 2.7% yield, a solid pharmaceutical business, and is clearly focused on its dividend. 
Via The Motley Fool
Topics Intellectual Property
News headline image
3 Reasons to Buy AbbVie Stock Like There's No Tomorrow ↗
It looks like a great buy-and-hold option. 
Via The Motley Fool
Topics Intellectual Property
News headline image
How Will AbbVie's $10.9 Billion Acquisition of Apogee Impact Its Dividend? ↗
There's no need to panic. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
52 53 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.